|
External validation antiplatelet CE-analysis:
"Robust methodology and valid conclusions"
The UK NHS Centre for Reviews and Dissemination assessed Pharmerit's cost-effectiveness analysis: "Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective." The Centre concluded that this economic evaluation was based on a robust methodology and that the authors’ conclusions were valid and appropriate. The assessment is publically available in the NHS Economic Evaluation Database (NHS EED).
|
